|
FI2753632T3
(fi)
|
2011-09-08 |
2023-08-02 |
Sage Therapeutics Inc |
Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
|
|
CA3152410A1
(en)
|
2011-10-14 |
2013-04-18 |
Sage Therapeutics, Inc. |
3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
|
|
SMT202000008T1
(it)
|
2012-01-23 |
2020-03-13 |
Sage Therapeutics Inc |
Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
|
|
PL2887944T3
(pl)
|
2012-08-21 |
2022-02-21 |
Sage Therapeutics, Inc. |
Allopregnanolon do leczenia lekoopornego stanu padaczkowego
|
|
ES2973320T3
(es)
|
2012-11-30 |
2024-06-19 |
Univ California |
Alopregnanolona para tratar, reducir o mitigar los síntomas de la depresión posparto
|
|
RS67266B1
(sr)
|
2013-03-13 |
2025-10-31 |
Sage Therapeutics Inc |
Neuroaktivni steroidi i postupci za njihovu upotrebu
|
|
RU2019126333A
(ru)
|
2013-04-17 |
2019-10-08 |
Сейдж Терапьютикс, Инк. |
19-нор нейроактивные стероиды и способы их применения
|
|
WO2014169831A1
(en)
|
2013-04-17 |
2014-10-23 |
Sage Therapeutics, Inc. |
19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
|
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
|
CN113527400B
(zh)
|
2013-04-17 |
2024-06-28 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
|
|
WO2015010054A2
(en)
|
2013-07-19 |
2015-01-22 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
AU2014308621C1
(en)
|
2013-08-23 |
2022-01-06 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2015195962A1
(en)
|
2014-06-18 |
2015-12-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
ES2970222T3
(es)
|
2014-06-18 |
2024-05-27 |
Sage Therapeutics Inc |
Oxiesteroles y procedimientos de uso de los mismos
|
|
EP3188734A4
(en)
|
2014-09-02 |
2018-01-10 |
The Texas A&M University System |
Method of treating organophosphate intoxication
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
MX2021004492A
(es)
|
2014-10-16 |
2022-12-05 |
Sage Therapeutics Inc |
Composiciones para el tratamiento de trastornos del snc.
|
|
SMT202000414T1
(it)
|
2014-10-16 |
2020-09-10 |
Sage Therapeutics Inc |
Composizioni e metodi per trattare disturbi del snc
|
|
ME03749B
(me)
|
2014-11-27 |
2021-04-20 |
Sage Therapeutics Inc |
KOMPOZICIJE I POSTUPCIZA LEČENJE POREMEĆAJA CNS-a
|
|
DK3250210T3
(da)
*
|
2015-01-26 |
2021-03-08 |
Sage Therapeutics Inc |
Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
|
|
JP6875996B2
(ja)
|
2015-02-20 |
2021-05-26 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド、組成物、およびその使用
|
|
MX390271B
(es)
|
2015-07-06 |
2025-03-20 |
Sage Therapeutics Inc |
Oxiesteroles y metodos de uso de los mismos
|
|
FI3828194T3
(fi)
|
2015-07-06 |
2025-07-17 |
Sage Therapeutics Inc |
Oxysteroleita ja menetelmiä niiden käyttämiseksi
|
|
MA42409A
(fr)
|
2015-07-06 |
2018-05-16 |
Sage Therapeutics Inc |
Oxystérols et leurs procédés d'utilisation
|
|
RU2766155C2
(ru)
|
2016-03-08 |
2022-02-08 |
Сейдж Терапьютикс, Инк. |
Нейроактивные стероиды, их композиции и применения
|
|
US20190330259A1
(en)
|
2016-04-01 |
2019-10-31 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
LT3481846T
(lt)
|
2016-07-07 |
2021-08-25 |
Sage Therapeutics, Inc. |
11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
WO2018013613A1
(en)
|
2016-07-11 |
2018-01-18 |
Sage Therapeutics, Inc. |
C17, c20, and c21 substituted neuroactive steroids and their methods of use
|
|
CN115974956A
(zh)
|
2016-08-23 |
2023-04-18 |
萨奇治疗股份有限公司 |
19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
|
|
JP7149266B2
(ja)
|
2016-09-30 |
2022-10-06 |
セージ セラピューティクス， インコーポレイテッド |
Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
|
|
MA46566A
(fr)
|
2016-10-18 |
2019-08-28 |
Sage Therapeutics Inc |
Oxystérols et leurs procédés d'utilisation
|
|
IL293231B2
(en)
|
2016-10-18 |
2025-10-01 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
|
KR102917075B1
(ko)
*
|
2018-02-11 |
2026-01-26 |
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 |
스테로이드 유도체 조절제, 그의 제조 방법 및 그의 용도
|
|
EP3750909B1
(en)
*
|
2018-02-11 |
2025-03-05 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Steroid derivative regulators, method for preparing the same, and uses thereof
|
|
CN114206900A
(zh)
|
2019-05-31 |
2022-03-18 |
萨奇治疗股份有限公司 |
神经活性类固醇及其组合物
|
|
US12215126B2
(en)
*
|
2020-05-21 |
2025-02-04 |
Brigham Young University |
Cationic steroidal antimicrobial compounds with endogenous groups
|
|
WO2023060067A1
(en)
|
2021-10-04 |
2023-04-13 |
Marinus Pharmaceuticals, Inc. |
Amorphous solid dispersion ganaxolone formulation
|